Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, March 29, 2024 | Back issues
Courthouse News Service Courthouse News Service

Cancer Drug

The 10th Circuit reversed a ruling in favor of biotech company Genentech in a dispute over the breast cancer drug Herceptin. Cancer treatment providers who purchased multi-dose vials of the drug claim the company failed to ensure each vial contained the labeled amount of the active ingredient. 

DENVER — The 10th Circuit reversed a ruling in favor of biotech company Genentech in a dispute over the breast cancer drug Herceptin. Cancer treatment providers who purchased multidose vials of the drug claim the company failed to ensure each vial contained the labeled amount of the active ingredient. 

Categories / Appeals, Business, Health

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...